Abstract-We investigated whether expression of genes previously implicated in arterial stiffening associates with crosssectional and longitudinal measures of arterial stiffness. Women from the Twins UK cohort (n=470, aged 39-81 years) had gene expression in lymphoblastoid cell lines measured using an Illumina microarray. Arterial stiffness was measured by carotid-femoral pulse wave velocity and carotid distensibility. A subsample (n=121) of women had repeat vascular measures after a mean±SD follow-up of 4.3±1.4 years. Associations of arterial phenotypes with gene expression levels were examined for 52 genes identified from previous association studies. 
A ge-related stiffening (arteriosclerosis) of large elastic arteries such as the aorta is an important predictor of future cardiovascular events, including myocardial infarction and stroke. 1, 2 The main cause of arterial stiffness is thought to be structural change of the extracellular matrix with an increase in arterial diameter and development of calcification. 3 Candidate gene and genome-wide association studies (GWAS) have identified genes potentially implicated in this process. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] However, genetic variants described to date account for small amounts of variance in arterial phenotypes and often do not replicate, presumably because of the difficulty in identifying rare variants, epigenetic modification, limited influence of common variants on gene expression and type 1 statistical error. 16, 17 Epigenetic modification, in particular, is likely to be an important regulator of gene expression and cardiovascular phenotype. 17 Furthermore, it is often difficult to determine what gene a single-nucleotide polymorphism affects and whether it is causal to the vascular phenotype. 18 This is a common problem with most polygenic conditions and thus there is interest in examining whether phenotypes may relate more closely to gene expression in accessible tissue, such as lymphoblastoid cell lines (LCLs) rather than to individual gene variants. 19 The aim of this study was thus to investigate whether gene expression levels in LCLs, which may participate in the arteriosclerotic process, of genes previously implicated in arterial stiffness associate with (1) arterial stiffness and diameter and (2) progression in arterial stiffness and diameter over a >4 year follow-up period.
population. 20 All women underwent measurement of carotid-femoral pulse wave velocity (cfPWV), carotid distensibility (CD), and diameter at baseline. A further 121 women had repeat vascular measures at a mean±SD follow-up of 4.3±1.4 years. Gene expression levels in LCLs were measured using Illumina Human HT-12 V3 Bead array. The study was approved by St. Thomas' Hospital Research Ethics Committee, and written informed consent was obtained from all subjects.
Vascular Measurements
Measurements were performed in a quiet temperature-controlled vascular laboratory (22-24°C) . Brachial blood pressure was measured using a validated oscillometric device (Omron 705CP, Omron, Tokyo, Japan) after subjects had been supine for at least 10 minutes. cfPWV was obtained using the SphygmoCor system (Atcor Medical, Sydney, Australia) by sequentially recording the carotid and femoral artery pulse by applanation tonometry with a high-fidelity transducer (Miller Instruments, Houston, TX). 21 Measurements were made in triplicate and mean values used for analysis.
Left carotid diameter was obtained using a Siemens CV70 ultrasound system (CV 70, Acuson-Siemens Corp, Mountain View, CA) with 13-MHz linear transducer or by GE VIVID7 (GE Healthcare) scanner with 12-MHz linear transducer. For visualization of the carotid arteries, subjects were in a supine position with the neck extended and tilted away from the side being scanned. Carotid diameter was measured from optimal longitudinal images 1 to 2 cm proximal to the carotid bifurcation in an area free of plaque. Automated wall tracking software (Medical Imaging Applications, Coralville, IA) was used to measure maximum and minimum diameter. CD was calculated as: CD=ΔD/(D×cPP), where ΔD is the difference between maximum and minimum diameter; D, the diastolic diameter; and cPP, the central pulse pressure. cPP was determined from radial pulse waveforms using the inbuilt transfer function within the Sphygmocor system from an average of 3 recordings calibrated to supine brachial blood pressure.
Muther Expression Data
Gene expression analysis was performed as described in the Muther study. 22 Briefly, peripheral blood samples were collected and LCLs generated through Epstein-Barr virus-mediated transformation of the B-lymphocyte component. 22 RNA was extracted from lysed LCLs using TRIzol Reagent (Invitrogen). RNA quality was assessed using Agilent 2100 BioAnalyzer (Agilent Technologies) and concentrations determined using the NanoDropND-1000 (NanoDrop Technologies). 22 Expression profiling was performed using the Illumina Human HT-12 V3 bead chip (Illumina Inc). For quality control, expression profiling was repeated 2 to 3 times on different bead chips. Log 2 -transformed expression signals were normalized with quantile normalization of the replicates of each individual followed by quantile normalization across all individuals.
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Selection of Genes
Fifty-two genes (Table S1 in the online-only Data Supplement) were selected from previously published studies examining genetic variants associated with arterial stiffness, 24 including GWAS 14, 15 and the association of arterial phenotypes with expression levels of these genes in LCLs examined.
Heritability and Pleiotropic Genetic Effects
Heritability of vascular measures and gene expression transcripts was estimated using the classic twin design as previously described. 21, 25 Intraclass correlation coefficients were compared for monozygotic (MZ) and dizygotic (DZ) twins with genetic influence inferred from similarity in MZ compared with DZ twins. Structural equation models were generated using Mx software (university of Virginia) specifying the variance-covariance matrices for MZ and DZ twins in terms of the additive genetic (A), common environment (C), and unique environmental (E, also including measurement error) components. The extent to which the correlation between arterial stiffness and gene transcripts could be determined by common genetic factors (bivariate heritability) was examined using extended models. These specified the variance-covariance matrices, with cross-twin, cross-trait correlations, in terms of the ACE parameters. The additive genetic correlation (r A ), shared environmental correlation (r C ), and unique environmental correlation (r E ), parameters were estimated using the method of maximum likelihood.
Statistical Analysis
Statistical analysis was performed using IBM SPSS Statistics version 22 (SPSS Inc, Chicago, IL). Subject characteristics are presented as mean±SD unless otherwise stated. Regression analysis was performed to examine the relation of each transcript with cfPWV adjusting for batch effect only (Model 1a). In secondary backward multivariate regression analysis, variables significantly associated with cfPWV in Model 1a (P≤0.10) were included as independent variables and further adjusted for age, mean arterial blood pressure, heart rate, and antihypertensive therapy (Model 2a). This analysis was repeated to examine the relation of gene transcripts with CD and diameter. Comparison between measures on the first and second visit were made using Students paired t test. The association of transcripts with progression in cfPWV (calculated as the difference in cfPWV between the first and second visits) was initially assessed in regression analysis adjusting for baseline cfPWV and batch effect only (Model 1b). The contribution of each transcript was then evaluated in secondary regression analysis, including all transcripts associated with progression in cfPWV that had a P value of ≤0.10 in Model 1b and further adjusting for baseline cfPWV, time between visits, baseline age, mean arterial blood pressure, and heart rate, baseline hypertension treatment and progression in mean arterial blood pressure and heart rate (Model 2b). Analysis was repeated to examine the relation of gene transcripts with CD and diameter.
Results
Relation of Gene Expression to cfPWV in CrossSectional Analysis
Characteristics (n=470, 188 MZ and 282 DZ) of the sample from the Twins UK cohort are shown in Table 1 . In univariate regression analysis ( Table 2 , Model 1a), cfPWV was most strongly correlated with gene transcripts involved in calcification (S100A12 and ENPP1), blood pressure (AGTR1), calcium-dependent activator of secretion (CADPS2), fibroblast growth factor 2 (FGFR2), and B-cell CLL/lymphoma 11B (BCL11B). In multivariate regression analysis ( Table 2 , Model 2a), only ENPP1 remained significantly positively correlated with cfPWV.
Heritability and Pleiotropic Genetic Effects
Intraclass correlation coefficients for ENPP1 and cfPWV were higher for MZ compared with DZ twins pairs suggesting a significant genetic influence: r=0.47 (95% CI, 0.26-0.64) versus r=0.19 (−0.01 to 0.36] for ENPP1 gene transcript and r=0.69 (0.57-0.79) versus r=0.30 (0.14-0.45) for cfPWV. Heritability estimates for ENPP1 and cfPWV were 45% (0.03%-0.60%) and 68% (0.42%-0.77%), respectively. Cross-twin, crosstrait correlations were higher in MZ (r=0.12) compared with DZ (r=0.07) twins and bivariate heritability analysis showed that 14% of the phenotypic correlation could be attributed to shared genetic factors ( Figure S1 ). cfPWV increased from 8.8±1.4 to 9.3±1.5 m/s (P<0.0001, Table 3 ). Of the variables associated with cfPWV in crosssectional analysis, only baseline expression levels of ENPP1 remained correlated with progression in cfPWV in univariate regression analysis (Table 4 , Model 1b). Other transcripts associated with cfPWV progression included collagen type IV α 1 (COL4A1), vascular cell adhesion molecule (VCAM1), ESR1, endothelin A receptor (EDNRA), elastin (ELN), and β2 adrenergic receptor (ADRB2). In multivariate regression analysis, transcripts most strongly correlated with progression of cfPWV were COL4A1 and ENPP1 (Table 4 , Model 2b; Figure  S2 ). Other transcripts weakly associated with progression of cfPWV included VCAM1, ESR1, EDNRA, and ELN.
To determine possible molecular pathways linking COL4A1 and ENPP1 to arterial stiffening, custom pathway analysis was performed using Ingenuity Pathway Analysis (Ingenuity Systems). Each gene was analyzed for downstream and upstream effects based on previous knowledge of expected effects of gene upregulation or downregulation in the Ingenuity Knowledge Base, which was limited to the human database. Analysis was trimmed to downstream regulators common for both COL4A1 and ENPP1. From Ingenuity Knowledge Base, we find that the transcriptional regulator CTNNB1, activated by the calcium-sensing receptor acts on both COL4A1 and ENPP1 (Figure) . Increased ENPP1 expression may either lead to arterial stiffening through an effect on arterial calcification, or it may induce osteopontin expression and influence the extracellular matrix through its effects on MMP2/9.
Relation of Gene Expression to CD and Diameter in Cross-Sectional Analysis
In univariate regression analysis, CD most closely correlated with expression of genes encoding for selectin P (SELP), Rho GTPase activating protein 1 (ARHGAP1), cytoskeletonassociated protein 5 (CKAP5), and matrix metalloproteinase 2 (MMP2, Table S2 , Model 1a). In multivariate regression analysis, CD remained negatively correlated with ARHGAP1, and positively correlated only with CKAP5 (Table S2 , Model 2a). In univariate regression analysis, carotid diameter was associated with expression of intracellular and vascular cell adhesion molecules (ICAM1 and VCAM1), MMP3, estrogen receptor (ESR1), and endothelial nitric oxide synthase (NOS3 ,  Table S3 , Model 1a). In multivariate regression analysis, carotid diameter remained positively correlated only with NOS3 expression (Table S3 , Model 2a).
Relation of Gene Expression to Change in CD and Diameter
During the follow-up period, CD decreased from 1.68±0.62 to 1.31±0.55 10 −3 mm Hg −1 (P<0.0001) and carotid diameter increased from 6.69±0.66 to 6.79±0.63 mm (P=0.006; Table 3 ). Of the variables correlated with CD in cross-sectional analysis, only expression of SELP remained correlated with a decrease in CD in univariate analysis (Table S4 , Model 1b). Other transcripts correlated with the decrease in CD included NOS3, α adducin (ADD1), aldosterone synthase (CYP11B2), BCL11B, ACE and calcium and integrin-binding protein (CIB2). In multivariate regression analysis (Table S4 , Model 2b), expression of NOS3 and ACE remained correlated with the decrease in CD; and BCL11B was correlated with the decrease in CD. In univariate analysis, transcripts correlated with change in carotid diameter included elongation factor Tu GTP-binding domain containing 1 (EFTUD1), fetuin A (AHSG), ACE, C-reactive protein (CRP), cytoskeletonassociated protein 5 (CKAP5), and ADAM metallopeptidase with thrombospondin type 1 motif (ADAMTS9). There were no genes associated with carotid diameter in cross-sectional analysis that associated with progression in carotid diameter (Table S5 , Model 1b). However expression of ACE related to progression in carotid diameter, as did EFTUD1 and ADAMTS9 (Table S5 , Model 2b).
Discussion
Age-related aortic stiffening characterized by increased cfPWV is thought to result from a change in the extracellular matrix and calcification in the aorta. 3 Twin and family studies estimate heritability of arterial stiffness to be ≈40%.
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Using a candidate gene approach, several single-nucleotide polymorphisms relating to extracellular matrix/calcification have been shown to associate with arterial stiffness, including polymorphisms of MMP, 4,5 collagen 1, 7 fibrillin 1, 6 and Model 1a examined the association of carotid-femoral pulse wave velocity with each transcript adjusting for batch effect only. Model 2a examined the association of all variables significantly associated with carotid-femoral pulse wave velocity in Model 1 (P≤0.10) after additional adjustment for age, mean arterial pressure, heart rate, and antihypertensive therapy in backward regression analysis.
ENPP1.
8 However, GWAS have identified only a small number of genetic variants reaching genome-wide significance.
To our knowledge, this is the first study to investigate the association of cross-sectional and longitudinal change in arterial stiffness to gene expression levels in LCLs. Expression of ENPP1, involved in vascular calcification, was independently correlated with cfPWV in both cross-sectional and longitudinal analysis. In addition, we found expression of COL4A1, which encodes for 1 component of type IV collagen, to significantly associate with progression in cfPWV (ie, arterial stiffening). The effect size for association of progression in cfPWV with ENPP1 and COL4A1 was greater than that for cross-section correlation (standardized β coefficients of 0.19 and 0.32). The finding of a correlation between expression of these genes and cfPWV suggests that these genes are functional mediators of a genetic association, and not just a marker for alternative genomic events. The variable associations of gene expression with cross-sectional and longitudinal measures of arterial stiffness in this study could have arisen by chance but could also be because of different mechanisms determining arterial stiffness at different vascular ages and this could potentially also explain variable results of previous cross-sectional GWAS.
ENPP1 common variant K121Q, has previously been associated with higher coronary calcification and increased cfPWV in patients with end-stage renal disease. 8 30, 31 Despite these findings, higher rather than lower, levels of ENPP1 were associated with arterial stiffening in this study. This is consistent with previous studies of vascular calcification where higher ENPP1 expression levels associated with aortic valve calcification in patients with aortic stenosis. 32 A possible explanation is that increased ENPP1 generates pyrophosphatase, which serves as a source of phosphate when hydrolyzed by alkaline phosphatase. 33 In culture media, high concentrations of phosphate induce matrix vesicle release from VSMC and expression of bone-related proteins. 34, 35 Patients with predialysis and dialysisdependent chronic kidney disease have high circulating calcium phosphate products and develop extensive calcification.
36
COL4A1 encodes for 1 components of type IV collagen, which is a structural component of basement membranes. In the media of the vascular wall, type IV collagen surrounds vascular smooth muscle cells. Gene mutations of COL4A1 associate with small-vessel brain disease, cerebral aneurysms, and eye defects. COL4A1 has previously been implicated in arterial stiffness in a GWAS performed in 4221 participants from the SardiNIA study and replicated in a further 1828 individuals 14 but not in a large meta-analysis that included >20 000 individuals. 15 The findings in this study support the role of COL4A1 in age-related arterial stiffening. Although the functional role of COL4A1 in arterial stiffness remains to be determined, degradation of type IV collagen may permit migration of VSMC into the internal elastic membrane and subendothelial space. These cells manufacture and secrete MMP2, proliferate and secrete extracellular matrix components that may all or independently contribute to arterial stiffening. 14 To elucidate a possible pathway linking COL4A1 and ENPP1 to arterial stiffening, we used Ingenuity Knowledge Database to identify possible upstream and downstream regulators. From Ingenuity Pathway Analysis, we find that both ENPP1 and COL4A1 are regulated by the transcription regulator CTNNB1, which is activated by the calcium-sensing receptor. This suggests that these 2 genes may act synergistically to increase arterial stiffness. Although existing evidence suggests a clear role for ENPP1 in vascular calcification, ENPP1 may also influence arterial stiffening by inducing osteopontin expression and affecting the extracellular matrix through effects on MMP2/9. Activated MMP2/9 are proteolytic enzymes involved in degradation of the extracellular matrix. Model 1b examined the association of progression in cfPWV with each transcript after adjustment for baseline cfPWV and batch effect only. Model 2b examined the association of all variables significantly associated with cfPWV progression in Model 1 (P≤0.10) after additional adjustment for time between visits, baseline age, mean arterial pressure, and heart rate; progression in mean arterial pressure and heart rate; and baseline hypertension treatment. cfPWV indicates carotid-femoral pulse wave velocity. The associations of arterial stiffness and stiffening we observed with gene expression in LCLs could arise through parallel gene expression in LCLs and in vascular tissue, participation of LCLs in the process of arterial stiffening or activation of downstream effectors by arterial stiffening, which influences endothelial cells and their interaction with leukocyte migration. 37 However, the involvement of genes involved in calcification suggests a causal role of these genes in arterial stiffening. A previous study examining the association of aortic stiffness with gene expression in aortic tissue obtained at the time of coronary artery bypass surgery implicated genes associated with cell signaling and the mechanical regulation of vascular structure that were not seen to associate with arterial stiffness in this study. The contrast between these findings and those of this study could be because of differential gene expression in LCLs and aortic tissue but could also be explained by the differing characteristics of the patients in the previous study who were older with clinical evidence of coronary artery disease. 38 Associations between cross-sectional and longitudinal measures of carotid diameter and distensibility with gene expression were generally less consistent that those for cfPWV and did not involve genes implicated in aortic calcification. However, it is notable that the carotid artery is a more muscular artery than the aorta and is less susceptible to calcification. Thus, it is possible that genes that influence muscular artery tone are relatively more important in the carotid artery than in the aorta and this might explain the observed associations of change in CD with NOS3 and ACE. We also observed a positive association between expression levels of BCLIIB and decrease in CD. BCL11B has previously been shown to be associated with arterial stiffness in a large meta-analysis that included >20 000 individuals 15 : BCL11B associated single-nucleotide polymorphism (rs7152623) was negatively associated with cfPWV and increased risk for cardiovascular disease. 15 The mechanism by which BCL11B may influence arterial stiffening is unknown but may involve transcriptional repression and activation.
Limitations
The study is limited to female twins; however, previous studies have shown this cohort to be comparable with the general population of women in the United Kingdom. 20 The results cannot, however, be generalized to men and future studies would need to confirm these findings in men. Because of the possibility of type 1 errors, our results need replication in a future larger cohort. Although twin pairs were randomly selected, individual subjects were not and this could make a small difference to the statistical results obtained. We measured gene expression and not protein expression, which may be more closely associated with vascular phenotypes. However, to our knowledge this is the first study to relate gene expression to both cross-sectional and longitudinal measures of arterial stiffness.
Perspectives
Previous genetic association studies that have identified gene variants associated with aortic stiffness do not necessarily implicate the causal gene. This study demonstrating an association of expression of ENPP1 and COL4A1 in LCLs, genes implicated in regulation of the extracellular matrix and arterial calcification, with arterial stiffness and stiffening supports a causal role for these genes in arterial stiffening. Different genes such as those regulating muscular arterial tone may be involved in stiffening of more muscular arteries.
In conclusion, an association of cfPWV and longitudinal change in cfPWV with expression of ENPP1 and COL41A in Figure. Conceptual pathway linking ENPP1 and COL4A1 to arterial stiffness. From Ingenuity Knowledge Base, we found that both COL4A1 and ENPP1 are directly acted on by the transcriptional regulator CTNNB1, which is activated by the calcium-sensing receptor (CASR). Increased ENPP1 expression may either lead to arterial stiffening through an effect on arterial calcification or by influencing the extracellular matrix by triggering SPP1 (osteopontin) and its effects on matrix metalloproteinase (MMP)2/9. Red lines denote hypothesized pathways based on current findings.
LCLs is consistent with a causal role for these genes in agerelated modification of the extracellular matrix and calcification of the aorta. 
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• ENPP1 was also a significant predictor of progression of cfPWV.
• Expression levels of COL4A1, which encodes for 1 component of type IV collagen, also associated with progression in cfPWV.
• Measures of carotid artery stiffening were associated with NOS3 and ACE expression, influencing vascular smooth muscle tone.
What Is Relevant?
• Age-related stiffening of large elastic arteries such as the aorta is an important predictor of future cardiovascular events, including myocardial infarction and stroke.
• Candidate gene and genome-wide association studies have identified genes potentially implicated in this process.
• The finding of a correlation between expression of these genes and cfPWV provides evidence that these genes are functional mediators of a genetic association, and not just a marker for alternative genomic events.
Summary
Our findings suggest that genes implicated in regulation of arterial calcification and extracellular matrix are involved in age-related increase in arterial stiffening as measured by cfPWV. Different genes may be involved in stiffening of more muscular arteries. Model 1b examined the association of each transcript with change in carotid diameter after adjustment for baseline values and batch effect only. Model 2b examined the association of all variables significantly associated with change in carotid diameter in Model 1 (P ≤ 0.10) after additional adjustment for time between visits, baseline age, MAP, and HR; progression in MAP and HR; and HT treatment. 
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